NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

Thrombolysis


Studies from Johann Wolfgang Goethe University have provided new information about pulmonary embolism



NewsRx
Thrombolysis Library
Library Home

This article was published in Biotech Business Week, which you can subscribe to online.

NewsRx
NewsRx
2009 AUG 3 - (NewsRx.com) -- According to a study from Mainz, Germany, "Elevated cardiac troponin T (cTnT) has been described in the setting of acute pulmonary embolism (PE) earlier, though currently it has no implication on the therapy in this setting. The protocol established in our institution recommends the use of fibrinolytic therapy as first-line therapy in these patients only when cTnT is elevated."

"This analysis was performed to evaluate the safety of this regimen in regard to 30-day mortality, morbidity and complications. A total of 192 consecutive patients with confirmed PE, presenting at our institution during 2000-2005, were recruited. Right ventricular function was determined echocardiographically. CTnT was determined in all patients on admission. without elevated cTnT were treated with anticoagulation alone, while patients with a TnT level above 0.1 ng/mL PE could be treated with thrombolysis on the discretion of the physician in charge. On day 30, cTnT elevation was associated with a higher mortality (P = 0.009). Moreover, in patients with intermediate-risk PE that were cTnT negative anticoagulation alone was safe showing a 30-day mortality of 1.8%, similar to low-risk PE (2.0%). In contrast to this patients with intermediate-risk PE with cTnT elevation showed a mortality rate of 20.8%, which was significantly higher (P < 0.001). In patients with intermediate-risk PE without elevated cTnT, anticoagulation alone seems to be a safe regimen. The midterm prognosis of these patients is as good as the prognosis of patients with low-risk PE," wrote F. Post and colleagues, Johann Wolfgang Goethe University.

The researchers concluded: "In this cohort of patients with PE, beginning with a more conservative treatment strategy per se did not lead to an unfavourable outcome."

Post and colleagues published the results of their research in Clinical Research in Cardiology (Decision for aggressive therapy in acute pulmonary embolism: implication of elevated troponin T. Clinical Research in Cardiology, 2009;98(6):401-408).

For additional information, contact F. Post, Johannes Gutenberg University Mainz, Medical Clinic 2, Langenbeckstr 1, D-55131 Mainz, Germany.

The publisher of the journal Clinical Research in Cardiology can be contacted at: Dr. Dietrich Steinkopff Verlag, Tiergartenstrasse 17, 69121 Heidelberg, Germany.

Keywords: Germany, Mainz, Cardiology, Clinical Research, Hematology, Pulmonary Embolism, Pulmonology, Therapy, Treatment, Johann Wolfgang Goethe University.

This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.

NewsRx Passes
Advertisement
------------------------
Security by Verisign PR Login